{"id":26587,"date":"2025-10-24T10:27:28","date_gmt":"2025-10-24T09:27:28","guid":{"rendered":"https:\/\/k2info.w.uib.no\/?p=26587"},"modified":"2025-10-24T10:42:29","modified_gmt":"2025-10-24T09:42:29","slug":"disputas-marte-karen-brattas-31-10-25","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2025\/10\/24\/disputas-marte-karen-brattas-31-10-25\/","title":{"rendered":"Defence- Marte Karen Bratt\u00e5s \u2013 31.10-25"},"content":{"rendered":"
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

FACULTY OF MEDICINE<\/strong><\/p>\n\n\n\n

UNIVERSITY OF BERGEN<\/strong><\/p>\n\n\n\n

PUBLIC DEFENCE \u2013 Ph.D. DEGREE<\/p>\n\n\n\n

Marte Karen Bratt\u00e5s<\/strong><\/p>\n\n\n\n

The candidate is affiliated with the Department of Clinical Science (Klinisk institutt 2).<\/em><\/p>\n\n\n\n

Main supervisor:Professor H\u00e5kon Reikvam
Co-supervisor: Ph.d. Kimberley Hatfield<\/em><\/p>\n\n\n\n

Pr\u00f8veforelesning: Fredag 31. oktober 2025 kl. 10.15<\/strong><\/p>\n\n\n\n

Sted:  Auditorium, Armauer Hansens Hus, Haukelandsveien 28<\/p>\n\n\n\n

Given topic: \"Acute myelogenous leukemia in an aging population - challenges and opportunities\"<\/p>\n\n\n\n

Defence: Friday 31 October 2025 at 12.15<\/strong><\/p>\n\n\n\n

Sted: Auditorium, Armauer Hansens Hus, Haukelandsveien 28<\/p>\n\n\n\n

Dissertation title: \u201cExploring the spleen tyrosine kinase (SYK) as a possible pharmacological target in human acute myeloid leukemia\u201d<\/p>\n\n\n\n

1st opponent: Professor Petter Quist Paulsen, NTNU<\/p>\n\n\n\n

2nd opponent: PhD Ellen Elisabeth Brodin, Akershus University Hospital   <\/p>\n\n\n\n

3rd member of the committee: Professor Camilla T\u00f8ndel<\/p>\n\n\n\n

The defense will be led by Associate Professor Thomas Knoop.<\/p>\n\n\n\n

Open to all interested parties<\/p>","protected":false},"excerpt":{"rendered":"

Marte Karen Bratt\u00e5s<\/p>\n

Location: Auditorium, Armauer Hansens Hus, Haukelandsveien 28<\/p>\n

Date: October 31 <\/p>\n

Dissertation title: \u201cExploring the spleen tyrosine kinase (SYK) as a possible pharmacological target in human acute myeloid leukemia\u201d<\/p>\n

Read more →<\/a><\/p>","protected":false},"author":5375,"featured_media":26588,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43439],"tags":[],"class_list":["post-26587","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ph-d"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/26587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/5375"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=26587"}],"version-history":[{"count":3,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/26587\/revisions"}],"predecessor-version":[{"id":26642,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/26587\/revisions\/26642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media\/26588"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=26587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=26587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=26587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}